You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: February 28, 2024

CABOMETYX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Cabometyx, and what generic alternatives are available?

Cabometyx is a drug marketed by Exelixis Inc and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and thirty-one patent family members in thirty-two countries.

The generic ingredient in CABOMETYX is cabozantinib s-malate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabozantinib s-malate profile page.

DrugPatentWatch® Generic Entry Outlook for Cabometyx

Cabometyx was eligible for patent challenges on November 29, 2016.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 10, 2032. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for CABOMETYX
Drug Prices for CABOMETYX

See drug prices for CABOMETYX

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CABOMETYX
Generic Entry Date for CABOMETYX*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CABOMETYX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jun Zhang, MD, PhDPhase 2
Children's Oncology GroupPhase 2/Phase 3
National Cancer Institute (NCI)Phase 2/Phase 3

See all CABOMETYX clinical trials

Pharmacology for CABOMETYX
Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Paragraph IV (Patent) Challenges for CABOMETYX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
CABOMETYX Tablets cabozantinib s-malate 20 mg, 40 mg and 60 mg 208692 1 2019-08-16

US Patents and Regulatory Information for CABOMETYX

CABOMETYX is protected by fifteen US patents and four FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of CABOMETYX is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting CABOMETYX

C-met modulator pharmaceutical compositions
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

C-Met modulator pharmaceutical compositions
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ADVANCED RENAL CELL CARCINOMA

Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxami- de, and crystalline forms therof for the treatment of cancer
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N'-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxami- de, and crystalline forms thereof for the treatment of cancer
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxami- de, and crystalline forms thereof for the treatment of cancer
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF RENAL CELL CARCINOMA

Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxami- de, and crystalline forms thereof for the treatment of cancer
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ADVANCED RENAL CELL CARCINOMA

Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxami- de, and crystalline forms thereof for the treatment of cancer
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF DIFFERENTIATED THYROID CANCER THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY

Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

c-Met modulators and methods of use
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

C-met modulators and method of use
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF RENAL CELL CARCINOMA

C-met modulators and method of use
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

C-met modulators and method of use
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ADVANCED RENAL CELL CARCINOMA

(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxami- de
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF DIFFERENTIATED THYROID CANCER THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY

C-met modulator pharmaceutical compositions
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

FDA Regulatory Exclusivity protecting CABOMETYX

INDICATED FOR TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB
Exclusivity Expiration: ⤷  Try a Trial

FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA, AS A FIRST-LINE TREATMENT IN COMBINATION WITH NIVOLUMAB
Exclusivity Expiration: ⤷  Try a Trial

THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
Exclusivity Expiration: ⤷  Try a Trial

TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (DTC) THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY OR INELIGIBLE
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-002 Apr 25, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-003 Apr 25, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-003 Apr 25, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-003 Apr 25, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-002 Apr 25, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Exelixis Inc CABOMETYX cabozantinib s-malate TABLET;ORAL 208692-002 Apr 25, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for CABOMETYX

When does loss-of-exclusivity occur for CABOMETYX?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 5155
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 12214322
Estimated Expiration: ⤷  Try a Trial

Patent: 17204877
Estimated Expiration: ⤷  Try a Trial

Patent: 19203745
Estimated Expiration: ⤷  Try a Trial

Patent: 20273307
Estimated Expiration: ⤷  Try a Trial

Patent: 22246429
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2013020362
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 26751
Estimated Expiration: ⤷  Try a Trial

China

Patent: 3459373
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 73262
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 3513
Estimated Expiration: ⤷  Try a Trial

Patent: 1391145
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 73262
Estimated Expiration: ⤷  Try a Trial

Patent: 19498
Estimated Expiration: ⤷  Try a Trial

Georgia, Republic of

Patent: 0217235
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 57574
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 7848
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 13598
Estimated Expiration: ⤷  Try a Trial

Patent: 14505109
Estimated Expiration: ⤷  Try a Trial

Patent: 16188216
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 13009116
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 4130
Estimated Expiration: ⤷  Try a Trial

Patent: 2808
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 73262
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 73262
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 1306072
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 2030447
Estimated Expiration: ⤷  Try a Trial

Patent: 140044782
Estimated Expiration: ⤷  Try a Trial

Patent: 190049907
Estimated Expiration: ⤷  Try a Trial

Patent: 200031711
Estimated Expiration: ⤷  Try a Trial

Patent: 210010671
Estimated Expiration: ⤷  Try a Trial

Patent: 210147117
Estimated Expiration: ⤷  Try a Trial

Patent: 230158644
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 05571
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 40509
Estimated Expiration: ⤷  Try a Trial

Patent: 1309650
Estimated Expiration: ⤷  Try a Trial

Patent: 1706249
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CABOMETYX around the world.

Country Patent Number Title Estimated Expiration
Taiwan I447108 ⤷  Try a Trial
Taiwan 201219371 C-Met modulator pharmaceutical compositions ⤷  Try a Trial
European Patent Office 2387563 SEL DE MALATE DE N-(4-{[6,7-BIS(MÉTHYLOXY)QUINOLIN-4-YL]OXY}PHÉNYL)-N'-(4-FLUOROPHÉNYL)CYCLOPROPANE-1,1-DICARBOXAMIDE ET FORMES CRISTALLINES DE CELUI-CI POUR LE TRAITEMENT DU CANCER (MALATE SALT OF N- (4- { [ 6, 7-BIS (METHYLOXY) QUINOLIN-4-YL]OXY}PHENYL-N' - (4 -FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE, AND CRYSTALLINE FORMS THEREOF FOR THE TREATMENT OF CANCER) ⤷  Try a Trial
Eurasian Patent Organization 038195 МАЛАТНАЯ СОЛЬ N-(4-{[6,7-БИС-(МЕТИЛОКСИ)ХИНОЛИН-4-ИЛ]ОКСИ}ФЕНИЛ)-N'-(4-ФТОРФЕНИЛ)ЦИКЛОПРОПАН-1,1-ДИКАРБОКСАМИДА И ЕЕ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАКА ПОЧЕК И ПЕЧЕНИ (MALATE SALT OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE AND USE THEREOF FOR THE TREATMENT OF KIDNEY AND LIVER CANCER) ⤷  Try a Trial
Croatia P20130458 ⤷  Try a Trial
Portugal 2210607 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CABOMETYX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2213661 43/2014 Austria ⤷  Try a Trial PRODUCT NAME: CABOZANTINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/890/001-003 (MITTEILUNG) 20140326
2213661 14C0067 France ⤷  Try a Trial PRODUCT NAME: CABOZANTINIB ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE COUVERTE PAR LE BREVET DE BASE,INCLUANT SES SELS PHARMACEUTIQUEMENT EQUIVALENTS.; REGISTRATION NO/DATE: EU/1/13/890 20140326
2213661 C02213661/01 Switzerland ⤷  Try a Trial PRODUCT NAME: CABOZANTINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66471 15.12.2017
2213661 CA 2014 00039 Denmark ⤷  Try a Trial PRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140321
2213661 PA2014033,C2213661 Lithuania ⤷  Try a Trial PRODUCT NAME: KABOZANTINIBAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321
2213661 300678 Netherlands ⤷  Try a Trial PRODUCT NAME: CABOZANTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.